Aradigm Inhaled Insulin Type 1 Diabetes Study Raises Efficacy Concern
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novo Nordisk and Aradigm may focus on type 2 diabetes only for their AERx iDMS inhaled insulin system NN1998 following disappointing glucose suppression results in a Phase III type 1 diabetes trial.
You may also be interested in...
Diabetes Drug Advances Are Highlight Of NMEs Pending In 2005
Highlights of NME class of 2005 could be advances in diabetes, with Lilly/Amylin’s exenatide and Amylin’s Symlin currently being reviewed and Pfizer’s inhaled insulin Exubera slated for filing early in the year. Other major pending NMEs include J&J’s dapoxetine for premature ejaculation and Solvay’s irritable bowel syndrome agent Calmactin (cilansetron)
Diabetes Drug Advances Are Highlight Of NMEs Pending In 2005
Highlights of NME class of 2005 could be advances in diabetes, with Lilly/Amylin’s exenatide and Amylin’s Symlin currently being reviewed and Pfizer’s inhaled insulin Exubera slated for filing early in the year. Other major pending NMEs include J&J’s dapoxetine for premature ejaculation and Solvay’s irritable bowel syndrome agent Calmactin (cilansetron)
Apidra Increased CV Events Likely Due To Baseline Imbalance, FDA Concludes
The higher incidence of cardiovascular events seen with Sanofi-Aventis’ Apidra in patients with type 1 diabetes appears to have been a result of baseline imbalances, NDA review documents suggest.